Supplementary Tables and Figures.

Table S1. Descriptive statistics regarding histological type and FIGO stage for patients with and without SSI.

	Total	Patients without SSI	Patients with SSI
Type of gynaecological cancer			
Ovarian	133 (35.8%)	121 (36.3%)	12 (31.6%)
Serous	83 (62.4%)	74 (61.2%)	9 (75.0%)
Clear cell	14 (10.5%)	12 (9.9%)	2 (16.7%)
Endometrioid	18 (13.5%)	17 (14.0%)	1 (8.3%)
Low grade	4 (3.0%)	4 (3.3%)	0 (0%)
Other	10 (10.6%)	10 (11.6%)	0 (0%)
Uterine	238(64.2%)	212 (63.7%)	26 (68.4%)
Serous	59 (24.8%)	53 (25.0%)	6 (23.1%)
Endometrioid	128 (53.8%)	114 (53.8%)	14 (53.8%)
Clear cell	10 (4.2%)	10 (4.7%)	0 (0%)
Carcinosarcoma	23 (9.7%)	21 (9.9%)	2 (7.7%)
Sarcoma	12 (5.0%)	9 (4.2%)	3 (11.5%)
Other	6 (2.5%)	5 (2.4%)	1 (3.9%)
FIGO stage			
Ovarian			
IA	25 (18.8%)	25 (19.8%)	0 (0%)
IB	2 (1.5%)	2 (1.6%)	0 (0%)
IC	9 (6.7%)	7 (5.8%)	2 (16.7%)
II	7 (5.3%)	7 (5.8%)	0 (0%)
IIIA	10 (7.5%)	9 (7.4%)	1 (8.3%)
IIIB	5 (3.8%)	4 (3.3%)	1 (8.3%)
IIIC	64 (48.1)	56 (46.2%)	8 (66.7%)
IV	11 (8.3%)	11 (9.1%)	0 (0%)
Uterine			
IA	106 (44.5%)	98 (46.2%)	8 (30.8%)
IB	34 (14.7%)	32 (15.1%)	2 (7.7%)
II	21 (8.8%)	19 (9.0%)	2 (7.7%)
IIIA	9 (3.8%)	8 (3.8%)	1 (3.8%)
IIIB	2 (0.8%)	2 (0.9%)	0 (0%)
IIIC	40 (16.8%)	34 (16.0%)	6 (23.1%)
IV	26 (10.9%)	19 (9.0%)	7 (26.9%)

Table S2. Univariate analysis of risk factors for SSI in patients with uterine cancers.

	Total (n=238)	Patients without SSI (n=212)	Patients with SSI (n=26)	P value
Median BMI	29.2 (17.9-51.9)	28.5 (17.9-50.8)	36.1 (20.9-51.9)	**0.003**
Diabetes Mellitus				0.700
Yes	40 (16.5%)	35 (16.2%)	5 (19.2%)	
No	202(79.9%)	181 (83.8%)	21 (80.8%)	
Smoking				**0.020**
Yes	11 (4.5%)	7 (3.2%)	4 (15.4%)	


No	231 (95.5%)	209 (96.8%)	22 (84.6%)	
Route of surgery				**<0.001**
Laparotomy	94 (38.8%)	72(33.3%)	22 (84.6%)	
Laparoscopy	148 (61.2%)	144 (66.7%)	4 (15.4%)	
Stage of disease				**0.026**
Stage I-II	159 (65.7%)	147 (92.5%)	12 (7.5%)	
Stage III-IV	83 (34.3%)	69 (83.1%)	14 (16.9%)	
Median Estimated blood loss (ml)	200.0 (50 – 5500)	150.0 (50 - 5500)	325 (50-3000)	**0.010**
ASA	3 (1-5)	3 (1-4)	3 (2-5)	0.378
Bowel resection				0.131
Yes	6 (2.5%)	4 (1.9%)	2 (7.7%)	
No	236 (97.5%)	212 (98.1%)	24 (92.3%)	
Intra-operative complications				**0.006**
Yes	13 (5.4%)	8 (3.7%)	5 (19.2%)	
No	229 (94.6%)	208 (96.3%)	21 (80.8%)	
Median Length of hospital stay (days)	1.0	1.0 (0-17)	4.0 (0-101)	**<0.001**
Re-surgery < 30 days				0.047
Yes	4 (1.7%)	2 (0.9%)	2 (7.7%)	
No	238 (98.3%)	214 (99.1%)	24 (92.3%)	
Re-admission < 30 days				**0.002**
Yes	11 (4.5%)	6 (2.8%)	5 (19.2%)	
No	231 (95.5%)	210 (97.2%)	21 (80.8%)	

Table S3. Multivariable logistic regression for risk factors for SSI in patients with uterine cancer

	p-value	**Odds Ratio**	**95% CI**
BMI <30 kg/m2 vs >30/kg/m2	0.038	2.987	1.063 - 8.390
Smoking	0.018	7.462	1.413- 39.394
Route of surgery (laparocopy vs laparotomy)	<0.001	0.128	0.040 - 0.414
Early versus Advanced stage of disease	0.271	1.703	0.660 - 4.399

Table S4. Univariate analysis for SSI in patients with ovarian cancer

Univariate analysis of risk factors for SSI in patients with ovarian cancer				
	Total (n=133)	**Patients without SSI (n=121)**	**Patients with SSI (n=12)**	**P value**
Median BMI	26.1 (14.8 - 40.8)	26.0 (14.8 - 40.8)	29.1 (18.4 - 33.7)	0.741
Diabetes Mellitus				0.362
Yes	17(12.8%)	17 (14.0%)	0 (0%)	
No	116 (87.2%)	104 (86.0%)	12 (100%)	
Smoking				0.123
Yes	7 95.3%)	5 (4.1%)	2 (16.7%)	
No	126 (94.7%)	116 (95.9%)	10 (83.3%)	
Route of surgery				1.000
Laparotomy	122 (91.7%)	111 (91.7%)	11 (91.7%)	
Laparoscopy	11 (8.3%)	10 (8.3%)	1 (8.3%	
Stage of disease				0.070
Stage I-II	28 (21.1%)	28 (23.1%)	0	
Stage III-IV	105 (78.9%)	93 (69.9%)	12 (100%0)	
Median Estimated bloodloss (ml)	300 (50 -11000)	300 (50-11000)	1500 (50-4500)	0.102
ASA	3.0	3.0	3.0	0.378
Bowel resection				0.188
Yes	41 (30.8%)	35 (28.9%)	6 (50.0%)	
No	92 (69.2%)	86 (71.1%)	6 (50.0%)	
Intra-operative complications				0.188
Yes	9 (6.8%)	7 (5.8%)	2 (16.7%)	
No	124 (93.2%)	114 (94.2%)	10 (83.3%)	
Median Length of hospital stay (days)	4 (0-16)	3 (0-16)	5 (0-15)	**0.005**
Re-surgery < 30 days				**0.002**
Yes	4 (3.0%)	1 (0.8%)	3 (2.3%)	
No	129 (97.0%)	120 (99.2%)	9 (75.0%)	
Re-admission < 30 days				**0.002**
Yes	13 (9.8%)	8 (6.0%)	5 (41.7%)	
No	120 (90.2%)	113 (93.4%)	7 (58.3%)	



Supplementary Figure S1. Kaplan-Meier survival plot for recurrence-free survival in the subgroup of patients with ovarian cancer stratified by presence or absence of SSI, HR 0.980 (95%CI 0.424-2.67), p = 0.962).